Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Myelodysplastic Syndromes × enzalutamide × 30 days × Clear all

Sponsor

Conditions

Prostatic Neoplasms 22 Prostatic Neoplasms, Castration-Resistant 4 Recurrence 2 Neoplasm Metastasis 2 Metastatic Castration-Resistant Prostate Cancer 2 mCRPC 1 Small Cell Lung Carcinoma 1 Prostate Cancer Metastatic 1 Prostate Adenocarcinoma 1 Primary Dysautonomias 1 Pathologic Complete Response 1 Neoplasms 1 Neoplasm, Residual 1 Metastatic Hormone-sensitive Prostate Cancer 1 Lymphoma, Follicular 1 Kidney Diseases 1 Hypertension 1 Dementia 1 Cognitive Dysfunction 1 Breast Neoplasms 1 Bites and Stings 1 Biochemically Recurrent Prostate Cancer 1

Interventions

venetoclax 17 Azacitidine 16 fludarabine 11 fludarabine phosphate 8 Cyclophosphamide 8 Biopsy 8 Whole-Body Irradiation 7 Specimen Handling 7 Decitabine 7 Injections 6 Granulocyte Colony-Stimulating Factor 6 Busulfan 6 decitabine and cedazuridine drug combination 5 Stem Cell Transplantation 5 Melphalan 5 Cytarabine 5 Mycophenolic Acid 4 Filgrastim 4 olutasidenib 3 X-Rays 3 Thiotepa 3 Mesna 3 Cyclosporins 3 Cyclosporine 3 Cladribine 3 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3 ruxolitinib 2 posaconazole 2 pevonedistat 2 enasidenib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡